Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Sichuan Kelun-Biotech Biopharmaceutical Co's Inventory Turnover for the
six
months ended in Jun. 2026 was 0.96.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sichuan Kelun-Biotech Biopharmaceutical Co's Inventory-to-Revenue for the
six
months ended in Jun. 2026 was 0.26.
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Sichuan Kelun-Biotech Biopharmaceutical Co's Inventory Turnover for the
six
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sichuan Kelun-Biotech Biopharmaceutical Co's Inventory to Revenue for the
six
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Sichuan Kelun-Biotech Biopharmaceutical Co Days Inventory Related Terms
Sichuan Kelun-Biotech Biopharmaceutical Co Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Kelun-Biotech Biopharmaceutical Co Days Inventory Chart
Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Days Inventory
902.04
71.37
27.28
48.46
109.58
Sichuan Kelun-Biotech Biopharmaceutical Co Semi-Annual Data
HKSE:06990 vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Kelun-Biotech Biopharmaceutical Co Days Inventory vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) has a Days Inventory of 189.89 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. This is 166% above median its historical median of 71.37. Over the past decade, Sichuan Kelun-Biotech Biopharmaceutical Co's Days Inventory has ranged from 27.28 to 902.04. According to the industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #293 out of 640 companies in the Biotechnology industry, placing it in the top 45.8%.
Is Sichuan Kelun-Biotech Biopharmaceutical Co's Days Inventory too high?
Sichuan Kelun-Biotech Biopharmaceutical Co's current Days Inventory of 189.89 is 166% above median its 10-year median of 71.37. Over the past 10 years, this metric has ranged from a low of 27.28 to a high of 902.04. The Biotechnology industry median Days Inventory is 183.75. Sichuan Kelun-Biotech Biopharmaceutical Co's value of 189.89 is 3.3% above this industry median. Based on the distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #293 out of 640 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sichuan Kelun-Biotech Biopharmaceutical Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Kelun-Biotech Biopharmaceutical Co's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #293 out of 640 companies for Days Inventory. This puts Sichuan Kelun-Biotech Biopharmaceutical Co in the upper half of its industry. The industry median Days Inventory is 183.75. Sichuan Kelun-Biotech Biopharmaceutical Co's value of 189.89 is 3.3% above this benchmark. Historically, Sichuan Kelun-Biotech Biopharmaceutical Co's own Days Inventory has ranged from 27.28 to 902.04 over the past decade. While the company's 10-year median is 71.37 vs. the industry median of 183.75, Sichuan Kelun-Biotech Biopharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.75, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sichuan Kelun-Biotech Biopharmaceutical Co's current Days Inventory of 189.89 is 3.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. For the Biotechnology industry, the median Days Inventory is 183.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Kelun-Biotech Biopharmaceutical Co's current Days Inventory is 189.89, which is 166% above median its own 10-year median of 71.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Kelun-Biotech Biopharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$254.91, compared to a current price of HK$523.00 — trading 105.2% above its estimated fair value. The current Days Inventory is 189.89, which is 166% above median its 10-year median of 71.37 and 3.3% above the Biotechnology industry median of 183.75. Sichuan Kelun-Biotech Biopharmaceutical Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990), the current Days Inventory is 189.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Overvalued in 2026?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co stock appears to be overvalued.
The current stock price of HK$523.00 is trading 105.2% above its estimated GF Value™ of HK$254.91.
GuruFocus considers Sichuan Kelun-Biotech Biopharmaceutical Co to be Significantly Overvalued.
Key valuation signals for HKSE:06990:
Days Inventory: 189.89 (166% above median its 10-year median of 71.37)
GF Value™: HK$254.91 vs. price of HK$523.00 (105.2% above fair value)
Industry Position: 3.3% above the Biotechnology median (#293 of 640)
No single metric tells the full story. See the HKSE:06990 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
44GF Score
Get the complete analysis for HKSE:06990
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06990 has been successfully added to your 
